Measuring Myeloperoxidase Activity as a Marker of Inflammation in Gut Tissue Samples of Mice and Rat

Materials and reagents

Reagents

1. di-Potassium hydrogen phosphate (K₂HPO₄) (VWR, catalog number: 71003, CAS number: 7758-11-4), store at room temperature

2. Dulbecco’s phosphate buffered saline (DPBS), including calcium and magnesium (Gibco, catalog number: 14040133), store at room temperature

3. Hexadecyltrimethylammonium bromide (Sigma-Aldrich, catalog number: H5882, CAS number: 57-09-0), store at room temperature

4. Hydrogen peroxide 30% (H₂O₂) (Merck, catalog number: 107209, CAS number: 7722-84-1), store at 4 °C

5. o-Dianisidine dihydrochloride (Sigma-Aldrich, catalog number: D3252, CAS number: 20325-40-0), store at 4 °C

6. Potassium dihydrogen phosphate (KH₂PO₄) (Merck, catalog number: 104873, CAS number: 7778-77-0), store at room temperature

7. Sodium chloride 0.9% for injection (NaCl) (B. Braun, catalog number: 76363, CAS number: 7647-14-5), store at room temperature

8. Deionized water (H₂O), prepared using the Elix^® water purification system (see Equipment), store at room temperature

   
   

Solutions

1. Potassium phosphate buffer (pH = 6.0) (see Recipes)

2. Homogenization buffer (see Recipes)

3. Assay reagent (see Recipes)

Recipes

1. Potassium phosphate buffer (pH = 6.0)

   1. Prepare a 50 mM KH₂PO₄ solution by dissolving 6.805 g of KH₂PO₄ in 1 L of deionized H₂O.

   2. Prepare a 50 mM K₂HPO₄ solution by dissolving 5.706 g of K₂HPO₄ in 0.5 L of deionized H₂O.

   3. Adjust the pH of the KH₂PO₄ solution by gradually adding the 50 mM K₂HPO₄ solution, until a pH of 6.0 is reached.




2. Homogenization buffer

   Dissolve 2.5 g of hexadecyltrimethylammonium bromide in 500 mL of potassium phosphate buffer.




3. Assay reagent (light sensitive; use amber bottles wrapped in silver foil to store this solution)

   1. Prepare a 1% H₂O₂ solution by adding 100 μL of a 30% H₂O₂ solution to 2,900 μL of the potassium phosphate buffer.

   2. Prepare a 0.05% H₂O₂ solution by adding 200 μL of a 1% H₂O₂ solution to 3,800 μL of the potassium phosphate buffer.

   3. Dissolve 66.8 mg of o-dianisidine dihydrochloride in 4 mL of 0.9% NaCl solution.

   4. Prepare the assay reagents by mixing 4 mL of 0.05% H₂O₂ solution, 4 mL of the o-dianisidine dihydrochloride solution, and 392 mL of the potassium phosphate buffer.

      
      

Laboratory supplies

1. Cryotubes Cryo.S^TM, 2 mL (Greiner Bio-One, catalog number: 126263)

2. Precellys^® tubes, 2 mL (Bertin Technologies, catalog number: 9000538)

3. Cuvettes, 4.2 mL (Sarstedt, catalog number: 67.741)

4. Reusable oral gavage needle, 10 G × 25 mm (PetSurgical, catalog number: AFN2425S)

5. Syringe with luer lock tip, 5 mL (Terumo, catalog number: SS*05SE1)

6. Dissection material (scissors, fine tweezers)

Equipment

1. Elix^® water purification system (Millipore, catalog number: ZLXS50020)

2. Progard^® TL1 Cl2 pretreatment tap water filter (Milli-Q, catalog number: PR0GTLCS1)

3. Handheld pH meter (Oakton Instruments, model: pH 6+, catalog number: 35613-22)

4. Precellys^® 24 tissue homogenizer (Bertin Technologies, catalog number: P000669-PR240-A)

5. Centrifuge (Eppendorf, catalog number: 5425R)

6. UV/Vis Spectrometer (ATI Unicam, model: UV2-100)

Software

1. Excel^® (Microsoft) or any other software suitable for basic data manipulation

Procedure

1. Tissue collection

   1. Euthanize the mouse by cervical dislocation. Alternatively, a different humane method of euthanasia such as carbon dioxide inhalation can be used.

   2. Carefully open the abdominal cavity without damaging the intestines by making a midline incision.

   3. Remove ±3 cm of the relevant part of the gastrointestinal tract of the abdominal cavity, place it in a Petri dish containing ice-cold DPBS solution, and flush with a gavage needle attached to a 5 mL syringe containing DPBS to remove the luminal content. Alternatively, fecal material can be removed by gently squeezing the intestines with a pair of tweezers.

   4. Clean the gut tissue by removing any remaining mesenteric fat and then cut open the intestines along the mesenteric border.

   5. Collect a representative tissue sample (0.5 cm × 0.5 cm; ± 20–30 mg), dry it on a paper towel, weigh it, place it in a cryovial, and subsequently freeze the specimen in liquid nitrogen. To remain unbiased, it is good practice to always collect samples in the same region of the gastrointestinal tract (i.e., always take the most distal or proximal part of the colon). Examples of tissue samples of correct size are shown in Figure 1.

   6. After collection of all mouse samples, store them at -80 °C until further experiments are performed.

      
      

      
      Figure 1. Gut tissue samples of an appropriate size for the myeloperoxidase (MPO) assay. The exact size depends on the animal species and inflammatory state of the tissue. From left to right, representative samples of distal colon (25 mg), proximal colon (27 mg), ileum (22 mg), and glandular stomach (22 mg) of a healthy C57BL/6J mouse are shown.

      
      

2. Tissue homogenization

   1. Take the tissue samples from the freezer, transfer them to Precellys^® tubes, and place these on ice. When labeling the Precellys^® tubes, place the identifier on the side of the tube since the homogenization procedure can make identifiers written on the cap illegible.

   2. Use a pipette to add 0.02 mL/mg tissue of homogenization buffer (Recipe 2) to the samples.

   3. Place the tubes in the homogenizer and dissociate the tissue samples (6,000 rpm; 20 s shaking > 20 s break > 20 s shaking > 60 s break).

   4. Place the tubes on ice and wait for 30 min to allow for the foam, which is formed during the homogenization, to disappear.

   5. Centrifuge the samples (18,000× g for 15 min at 4 °C).

   6. Use a pipette to collect the supernatant in 1.5 mL Eppendorf tubes and place these on ice. The pellet can be discarded.




3. Myeloperoxidase activity assay

   1. Start the UV/Vis spectrometer and specify the necessary settings:

      1. Measurements are kinetic.

      2. Absorbance is measured at a wavelength of 460 nm (bandwidth 2.0 nm).

      3. The change in absorbance is measured during the first 60 s after the start of the chemical reaction.

   2. Open the lid of the spectrophotometer and place a 3 mL cuvette in the cuvette holder of the device. Pay attention to the correct orientation of the cuvette, i.e., with the clear windows in line with the light source and detector.

   3. Use a pipette to add 2,900 μL of assay reagent (Recipe 3) to the cuvette.

   4. Use a pipette to add 100 μL of sample supernatant to the cuvette, mix the sample by repetitive pipetting (5–10 times using a pipette set at 2 mL), close the lid of the spectrophotometer, and then promptly start the spectrophotometric measurement.

   5. After the 60-second measurement, note the absolute absorption values at 0 and 60 s in Excel.

   6. Replace the cuvette by a clean one and repeat the procedure for the other samples. Ideally, the assay is performed in duplo or in triplo.

Data analysis

Calculation of MPO activity in tissue samples

1. Calculate the change in absorbance (ΔAbs) by subtracting the measured absorbance at 0 s from the absorbance at 60 s.

2. Derive the MPO activity of the sample by implementing Beer’s law:

   
   

   

   
   

   where ΔC is the change in concentration of the oxidized form of o-dianisidine in μM/min; ΔAbs is the change in absorbance of the sample after 60 s; ϵ is the extinction coefficient of oxidized o-dianisidine, which has been determined to be 1.13 × 10⁴ μM/cm for a wavelength of 460 nm at room temperature (Worthington and Worthington, 2011); and b is the optical path length, which is 1 cm for the cuvettes recommended in this protocol.

3. Express the MPO activity in units per gram of tissue. A unit of MPO is defined as the enzymatic activity that converts 1 μmol of hydrogen peroxidase to water in 1 min at room temperature and can be calculated using:

   
   

   

   
   

   where Act is the enzymatic activity in unit per gram of tissue; ΔC is the change in concentration of the oxidized form of o-dianisidine in μM/min; V_reac is the volume of the supernatant that is used in the cuvette, which is 0.1 mL in the described protocol; and C_sn is the concentration of the generated supernatant, which is 0.05 g of tissue per milliliter of homogenization buffer.

   Note that for samples with very high activity levels, the supernatant could be further diluted to obtain accurate measures of enzyme activity.

   
   

Data example

To illustrate the assay, 12-week-old female C57BL/6J mice were exposed to 3% DSS for seven days via autoclaved drinking water to induce acute colitis (Kim et al., 2012; Breugelmans et al., 2020). Control mice received autoclaved drinking water without the addition of DSS. After a one-week treatment, DSS-treated mice showed signs of colitis, i.e., weight loss, diarrhea, and rectal bleeding. To confirm the inflammatory state of the animals, MPO activity was determined in tissue supernatant derived from the distal colon. To illustrate the importance of determining MPO activity instead of MPO content, a commercially available ELISA (Invitrogen, catalog number: EMMPO) was performed to quantify MPO protein expression levels on the same tissue supernatant, according to the instructions of the manufacturer.

MPO activity in the distal colon of DSS-treated mice was significantly higher than in control animals [DSS: 5.46 (4.05–8.14) U/g tissue vs. control: 0.30 (0.22–0.47) U/g tissue, p < 0.01 for n = 6 animals/group, Figure 2A]. Despite the increased peroxidase activity in the distal colon of DSS-exposed mice, the MPO protein expression did not differ between the groups [DSS: 42.67 (34.53–58.75) ng/g tissue vs. control: 45.05 (39.60–49.92) ng/g tissue, p = 0.78, Figure 2B]. Notably, MPO protein content and enzymatic activity were not correlated (r_S = 0.30, p = 0.34, Figure 2C). Potentially, the capacity of gut tissue to inhibit peroxidase activity is lost upon the exposure to DSS (Ormrod et al., 1987).

Figure 2. MPO activity and protein expression levels in a mouse model for acute DSS-induced colitis. A) MPO activity, measured according to our protocol, is increased in DSS-exposed mice. B) MPO protein expression, measured using an ELISA kit, is not altered by exposure to DSS. C) MPO protein expression and enzymatic activity are not correlated. All quantifications were performed in duplo. Analysis by means of a Mann-Whitney U test (A, B) or Spearman’s rank correlation test (C) for n = 6 animals per group. DSS, dextran sulfate sodium; MPO, myeloperoxidase activity.

Validation of protocol

This MPO assay was previously used by our group to quantify inflammation in acute and chronic colitis models in both mice and rat (Moreels et al., 2004; Ruyssers et al., 2009; Vermeulen et al., 2011). We demonstrated that MPO activity correlated well with other markers for inflammation in TNBS-induced colitis in the rat (Vermeulen et al., 2011) and in the adoptive transfer colitis model in mice (Heylen et al., 2013).

General notes and troubleshooting

For the tissue homogenization to be successful, it is best to avoid the use of large tissue samples. We have observed that the best results are obtained when the gastrointestinal tract is cut open longitudinally. The Precellys^® tubes allow for a maximum volume of ± 1.5 mL, corresponding to a maximum tissue weight of 75 mg.

Our protocol expresses the obtained MPO activity in units per gram of tissue. Alternatively, one can express the MPO activity in units per gram of tissue protein content. To this end, total protein content needs to be assessed on the tissue supernatant obtained in section B. Commercially available kits, such as the Pierce BCA protein assay (Thermo Fisher, catalog number: 23227) can be used for this measurement.

Sections B (tissue homogenization) and C (myeloperoxidase assay) can be performed on separate days. To do so, collect the tissue supernatant in cryovials and store these at -80 °C until the MPO activity is to be determined.

In our hands, intra-assay variability for an assay performed in duplo was 8.89% for DSS-exposed animals and 75.51% for controls. Note that the high coefficient of variability in control animals could be attributed to the very low read-out values in this group.

Acknowledgments

This work was supported by a BOF-TOP grant of the University of Antwerp (grant number 35018). The quantification of MPO activity in gastrointestinal tissue supernatant was adapted from the work of Krawisz and colleagues (Krawisz et al., 1984).

The authors would like to thank the lab technicians of the Laboratory of Experimental Medicine and Paediatrics for their help with experiments and for critically reviewing the protocol. The graphical abstract was constructed using BioRender.

Competing interests

The authors declare that there are no conflicts of interest.

Ethical considerations

Animal experiments were performed after obtaining approval of the Ethical Committee for Animal Testing of the University of Antwerp (ECD-file 2021-88).

References

1. Breugelmans, T., Van Spaendonk, H., De Man, J. G., De Schepper, H. U., Jauregui-Amezaga, A., Macken, E., Lindén, S. K., Pintelon, I., Timmermans, J. P., De Winter, B. Y., et al. (2020). In-depth study of transmembrane mucins in association with intestinal barrier dysfunction during the course of T cell transfer and DSS-induced colitis. J Crohns Colitis 14(7): 974-994.
2. Erben, U., Loddenkemper, C., Doerfel, K., Spieckermann, S., Haller, D., Heimesaat, M. M., Zeitz, M., Siegmund, B. and Kühl, A. A. (2014). A guide to histomorphological evaluation of intestinal inflammation in mouse models. Int J Clin Exp Pathol 7(8): 4557-4576.
3. Heylen, M., Deleye, S., De Man, J. G., Ruyssers, N. E., Vermeulen, W., Stroobants, S., Pelckmans, P. A., Moreels, T. G. and De Winter, B. Y. (2013). Colonoscopy and μPET/CT are valid techniques to monitor inflammation in the adoptive transfer colitis model in mice. Inflamm Bowel Dis 19(5): 967-976.
4. Khan, S. S., Smith, M. S., Reda, D., Suffredini, A. F. and McCoy, J. P. Jr. (2004). Multiplex bead array assays for detection of solubile cytokines: comparisons of sensitivity and quantitative values among kits from multiple manufacturers. Cytometry B Clin Cytom 61(1): 35-39.
5. Kim, J. J., Shajib, S., Manocha, M. M. and Khan, W. I. (2012). Investigating intestinal inflammation in DSS-induced model of IBD. J Vis Exp (60): 3678.
6. Kuebler, W. M., Abels, C., Schuerer, L. and Goetz, A. E. (1996). Measurement of neutrophil content in brain and lung tissue by a modified myeloperoxidase assay. Int J Microcirc Clin Exp 16(2): 89-97.
7. Krawisz, J. E., Sharon P. and Stenson W. F. (1984). Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity: Assessment of inflammation in rat and hamster models. Gastroenterology 87(6): 1344-1350.
8. Mizoguchi, A. (2012). Animal models of inflammatory bowel disease. Prog Mol Biol Transl Sci 105(1): 263-320.
9. Moreels, T. G., De Man, J. G., De Winter, B. Y., Herman, A. G. and Pelckmans, P. A. (2001). How to express pharmacological contractions of the inflamed rat intestine. Naunyn Schmiedebergs Arch Pharmacol 364(6): 524-533.
10. Moreels, T. G., Nieuwendijk R. J., De Man J. G., De Winter B. Y., Herman A. G., Van Marck E. A. and Pelckmans P. A. (2004). Concurrent infection with Schistosoma mansoni attenuates inflammation induced changes in colonic morphology, cytokine levels, and smooth muscle contractility of trinitrobenzene sulphonic acid induced colitis in rats. Gut 53(1): 99-107.
11. Ormrod, D. J., Harrison, G. L. and Miller, T. E. (1987). Inhibition of neutrophil myeloperoxidase activity by selected tissues. J Pharmacol Methods 18(2): 137-142.
12. Ruyssers, N. E., De Winter, B. Y., De Man, J. G., Loukas, A., Pearson, M. S., Weinstock, J. V., Van den Bossche, R. M., Martinet, W., Pelckmans, P. A. and Moreels, T. G. (2009). Therapeutic potential of helminth soluble proteins in TNBS-induced colitis in mice. Inflamm Bowel Dis 15(4): 491-500.
13. Solomon, L., Mansor, S., Mallon, P., Donnelly, E., Hoper, M., Loughrey, M., Kirk, S. and Gardiner, K. (2010). The dextran sulphate sodium (DSS) model of colitis: an overview. Comp Clin Pathol 19(1): 235-239.
14. Schultz, J. and Kaminker, K. (1962). Myeloperoxidase of the leucocyte of normal human blood. I. Content and localization. Arch Biochem Biophys 96: 465-467.
15. Vermeulen, W., De Man, J. G., Nullens, S., Pelckmans, P. A., De Winter, B. Y. and Moreels, T. G. (2011). The use of colonoscopy to follow inflammatory time course of TNBS colitis in rats. Acta Gastroenterol Belg 74(2): 304-311.
16. Worthington, K. and Worthington, V. (2011). Worthington Enzyme Manual. Worthington Biochemical Corporation. 13feb2023. https://www.worthington-biochem.com/products/peroxidase/manual
17. Xavier, R. J. and Podolsky, D. K. (2007). Unravelling the pathogenesis of inflammatory bowel disease. Nature 448(7152): 427-434.
18. Xia, Y. and Zweier, J. L. (1997). Measurement of myeloperoxidase in leukocyte-containing tissues. Anal Biochem 245(1): 93-96.
19. Yan, Y., Kolachala, V., Dalmasso, G., Nguyen, H., Laroui, H., Sitaraman, S. V. and Merlin, D. (2009). Temporal and spatial analysis of clinical and molecular parameters in dextran sodium sulfate induced colitis. PLoS One 4(6): e6073.